Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03041038 · ClinicalTrials.gov registry record · Phase 2
The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
A Phase 2 study of Netherton Syndrome and Ichthyosis, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT03041038 is a Phase 2 study of Netherton Syndrome and Ichthyosis that has completed, run by Northwestern University. The registered enrollment target is 20 participants, below the 25-participant average among 6 other Netherton Syndrome trials with a reported enrollment target (20% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03041038, a Phase 2 study of Netherton Syndrome and Ichthyosis, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
The ichthyoses are a group of lifelong genetic disorders which share characteristics of generalized skin thickening, scaling and underlying cutaneous inflammation. There are no therapies based on growing understanding of what causes the disease. However, there have been recent discoveries of marked elevations in expression of interleukin-17A (IL-17A) and IL-17-related cytokines in the skin of individuals with ichthyosis, which may explain the inflammation. Investigators propose that IL-17-targeting therapeutics will safely suppress the inflammation and possibly the other features of ichthyosis, improving quality of life.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Secukinumab
Study Locations (2)
Illinois
- Department of Dermatology, Northwestern University Feinberg School of Medicine - Chicago
New York
- Department of Dermatology Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-12 |
| Est. Completion | 2020-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03041038
The ClinicalTrials.gov registry entry for NCT03041038 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 25-participant average among 6 other Netherton Syndrome trials with a reported enrollment target (20% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Netherton Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03041038 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT03041038 about?
NCT03041038 is a clinical study titled "The Efficacy and Safety of Secukinumab in Patients With Ichthyoses". The ichthyoses are a group of lifelong genetic disorders which share characteristics of generalized skin thickening, scaling and underlying cutaneous inflammation. There are no therapies based on growing understanding of what causes the disease. However, there have been recent discoveries of marked ...
What is the current status of trial NCT03041038?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2016-12. Estimated completion is 2020-08-31.
What conditions does trial NCT03041038 study?
This clinical trial studies the following conditions: Netherton Syndrome, Ichthyosis, Lamellar Ichthyosis, Autosomal Recessive Congenital Ichthyosis, Congenital Ichthyosiform Erythroderma.
What interventions are being tested in trial NCT03041038?
The interventions under investigation include: Placebo (DRUG), Secukinumab (DRUG).
Who is sponsoring clinical trial NCT03041038?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03041038 being conducted?
This trial has 2 study locations across Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Netherton Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
RECRUITING · Phase 2
-
Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
RECRUITING · Phase 2
-
Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
RECRUITING · Phase 1
-
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
RECRUITING · Phase 1
-
Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.